Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12913433 | 1.00 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL7143320 | 1.00 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL15325041 | 0.92 | — | — | |
| SCHEMBL6242702 | 0.87 | EPHX1 (0.46) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL27713854 | 0.84 | EPHX1 (0.42) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL29295753 | 0.81 | KDM4E (0.41) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL1188709 | 0.80 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL2055541 | 0.80 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 | |
| Cyclohexane SCHEMBL18344237 | 0.80 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL1595664 | 0.80 | EPHX1 (0.44) | EPHX1CA12CA1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-RE42164-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-RE41894-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-20100168175-A1 | ATPENINS | BAYER CROPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168175-A1 | ATPENINS | BAYER CROPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
| WO-2010069495-A1 | ATPENINS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-RE41356-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-05-25 | — | — | US | disclosed |
| EP-1105413-B1 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2009-04-29 | — | — | EP | disclosed |
| EP-2028186-A2 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-02-25 | — | — | EP | disclosed |
| US-RE40525-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| EP-1577090-B1 | Lithographic printing plate precursor | FUJIFILM CORP (JP) | 2007-06-06 | — | — | EP | disclosed |
| CN-1191054-C | Vitamin C delivery system | UNILEVER PLC (NL) | 2005-03-02 | — | — | CN | disclosed |
| CN-1222848-A | Vitamin C delivery system | UNILEVER PLC (NL) | 1999-07-14 | — | — | CN | disclosed |
| US-4067886-A | REACTING KETONES AND KETALS WITH HALOGEN | LEVER BROTHERS COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | EPHX1 1446/4885CA12 3183/4885CA1 3625/4885 |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | EPHX1 1120/4885CA12 4017/4885CA1 4162/4885 |
| US-20100168175-A1 | ATPENINS | ATP5ME, ATP5MK, ATP5F1B | EPHX1 1027/4885CA12 4879/4885CA1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.